For families affected by Duchenne Muscular Dystrophy (DMD), navigating treatment options can be complex. Alongside standard treatments and clinical trials, there are other potential pathways that may provide access to medicines before they are fully approved or commercially available in a particular country.
One of these pathways is an Early Access Program (EAP).
To help make this topic easier to understand, BAP Pharma has collaborated with DMD Pathways to develop Understanding Early Access Programs (EAPs): A Guide for the Duchenne Muscular Dystrophy (DMD) Community. The guide provides practical, accessible information to help families understand what early access means, when it may be relevant and what questions they may wish to discuss with their healthcare team.
What are Early Access Programs? (EAPs)
Early Access Programs can allow patients with serious or rare conditions to access promising medicines that are not yet fully approved or available in their country.
These medicines may still be in development or awaiting regulatory approval, may have shown promising results in clinical trials, or may not yet be licensed as a standard treatment option. Access is generally subject to specific eligibility criteria, with requests made by a treating physician on behalf of the patient.
Importantly, Early Access Programs are not the same as clinical trials.
Clinical trials are primarily designed to generate evidence about how a medicine works, its safety and who may benefit from it. EAPs, by contrast, focus on providing access to a medicine for eligible patients outside of a clinical trial setting. This may be particularly relevant where a patient is not eligible for a trial or where a trial has finished but the medicine has not yet received approval.
As with any treatment decision, participation in an Early Access Program should be discussed with a healthcare professional, who can advise whether it may be an appropriate option based on an individual’s circumstances.
Why can Early Access be important for DMD?
In rare diseases such as DMD, there can be a significant gap between promising clinical trial results and a medicine becoming officially approved and available to patients.
The guide highlights that this approval process can take several years. Early Access Programs can potentially help bridge this gap, particularly where treatment options are limited, a patient is not eligible for a clinical trial, or a trial has ended but the medicine is not yet approved.
Early access can also be referred to by different names depending on the country or regulatory framework, including Compassionate Use, Expanded Access, Managed Access and Named Patient Programs. While these approaches share a common goal of enabling access to medicines outside standard commercial routes, their requirements, processes and potential costs can differ.
Understand the Benefits & Considerations
Early Access Programs can provide an additional potential treatment pathway, including earlier access to promising medicines and more options where treatment choices may be limited.
However, the guide also emphasises the importance of understanding the limitations. Long-term data may be limited, programs can change or stop, eligibility depends on individual circumstances and local regulations, and there may be practical or financial considerations such as hospital visits, monitoring or additional expenses.
Understanding both the potential opportunities and limitations can help patients and families make informed decisions and have meaningful discussions with their healthcare team. This is why discussions with a treating doctor or specialist are an important part of exploring whether an Early Access Program may be appropriate.
Questions families can ask their healthcare team
One of the most practical sections of the guide is a list of questions families can take to their next appointment.
These include:
- Are there any Early Access Programs available for DMD?
- Are there treatments currently in development that may be relevant?
- Would I or my loved one be eligible?
- What are the potential benefits and risks?
- Would there be any costs involved?
- How would treatment be given and monitored?
- What happens if the treatment doesn’t work or causes side effects?
The aim isn’t to provide all the answers, but to help start a conversation and encourage informed discussions with a treating physician or specialist about the options that may be available.
Helping Families Navigate the Treatment Landscape
The guide also introduces DMD Pathways, which aims to help families understand what treatments, clinical trials and access pathways may exist globally.
DMD Pathways provides information designed to make a complex treatment landscape easier to navigate, while emphasising that it does not provide medical advice. Its resources can help families prepare for conversations with their healthcare team and connect with relevant organisations and information.
The DMD Pathways website currently provides resources including information on approved treatments globally and a clinical trials hub designed to make Duchenne research easier to explore.
A Final Thought
Early Access Programs may not be appropriate or available for every patient, and eligibility and availability can vary between countries and individual circumstances. Whether you are newly exploring the treatment landscape or looking to better understand the options that may be available, knowledge can be an important first step towards asking informed questions and having productive conversations with your healthcare team.
Download the DMD Pathways Guide to learn more about Early Access Programs and the questions to consider when discussing potential options with your healthcare team.
